Published • loading... • Updated
Traws Delays Influenza Study After UK Regulatory Setback
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Traws Delays Influenza Study After UK Regulatory Setback
NEWTOWN, PA — Traws Pharma Inc. (NASDAQ: TRAW) has deferred a planned Phase 2a human influenza challenge study of its lead antiviral candidate tivoxavir marboxil after receiving unfavorable feedback from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency, creating a setback for the company’s influenza development program. The regulatory review halted plans to test the drug candidate in a controlled human influenza study, de…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
